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Abstract
Integrin b3 is seen as a key anti-angiogenic target for cancer
treatment due to its expression on neovasculature, but the role
it plays in the process is complex; whether it is pro- or anti-
angiogenic depends on the context in which it is expressed. To
understand precisely b3’s role in regulating integrin adhesion
complexes in endothelial cells, we characterised, by mass spec-
trometry, the b3-dependent adhesome. We show that depletion
of b3-integrin in this cell type leads to changes in microtubule
behaviour that control cell migration. b3-integrin regulates
microtubule stability in endothelial cells through Rcc2/Anxa2-
driven control of active Rac1 localisation. Our findings reveal
that angiogenic processes, both in vitro and in vivo, are more
sensitive to microtubule targeting agents when b3-integrin
levels are reduced.
Keywords adhesome; endothelial; integrins; microtubules
Subject Categories Cell Adhesion, Polarity & Cytoskeleton; Methods &
Resources; Vascular Biology & Angiogenesis
DOI 10.15252/embr.201744578 | Received 5 June 2017 | Revised 25 April 2018 |
Accepted 27 April 2018
EMBO Reports (2018) e44578
Introduction
Angiogenesis, the formation of new blood vessels from those that
already exist, plays an essential role in tumour growth [1]. As such,
targeting angiogenesis is seen as crucial in many anti-cancer strate-
gies [2]. Therapies directed against vascular endothelial growth
factor (VEGF) and its major receptor, VEGF-receptor-2 (VEGFR2),
whilst effective in a number of cancers, are not without side-effects
due to the role this signalling pathway plays in vascular homeosta-
sis [3]. Fibronectin (FN)-binding endothelial integrins, especially
avb3- and a5b1-integrins, have emerged as alternative anti-
angiogenic targets because of their expression in neovasculature
[4,5]. However, neither global nor conditional knockouts of these
integrins block tumour angiogenesis in the long term [6–8], and
clinical trials of blocking antibodies and peptides directed against
these extracellular matrix (ECM) receptors have been disappointing
[9,10]. To gain novel insight into how avb3-integrin regulates
outside-in signal transmission [11], we have undertaken an unbi-
ased analysis of the molecular composition of the mature endothe-
lial adhesome and profiled changes that occur when b3-integrin
expression is manipulated. In so doing, we have uncovered b3-
integrin-dependent changes in microtubule behaviour that regulate
cell migration.
Results and Discussion
The isolation and analysis of integrin adhesion complexes (IACs) by
mass spectrometry (MS) is difficult because of the low affinity and
transient nature of the molecular interactions occurring at these
sites. However, using cell-permeant chemical cross-linkers improves
recovery of IAC proteins bound to either FN-coated microbeads [12]
or plastic dishes [13]. These advances have led to the characterisa-
tion of IACs from a number of cell types. Whilst a core consensus
adhesome (the network of structural and signalling proteins
involved in regulating cell-matrix adhesion [14]) can be defined
[12], the composition and stoichiometry of the meta-adhesome
depend on the cell type being analysed, the integrin-receptor reper-
toire expressed by that cell type, and any imposed experimental
conditions. To examine the composition of the endothelial adhe-
some, we isolated lung microvascular endothelial cells (ECs) from
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C57BL6/129Sv mixed background mice and immortalised them with
polyoma-middle-T-antigen by retroviral transduction [15]. As our
main interest was in establishing how b3-integrin influences the
endothelial adhesome, we adhered cells to FN for 90 min, which
allows b3-rich (mature) focal adhesions (FAs) to form [16]. To
distinguish integrin-mediated recruitment of proteins from non-
specific background, we also plated cells on poly-L-lysine (PLL) as a
negative control (adhesion to PLL does not depend on integrins).
Visualisation of neuropilin-1 staining in whole cells showed that this
protein, which we previously demonstrated is present in the mature
EC adhesome [17], co-localises with talin-1 in FAs when cells are
plated on FN, but not PLL (Fig 1A). For all proteomics experiments,
we cross-linked FAs using the cell-permeant and reversible cross-
linkers DPDPB and DSP (see Materials and Methods) for 5 min.
Cells were lysed and subjected to a high shear flow water wash to
remove non-cross-linked material. Crosslinking was reversed, and
samples were precipitated and concentrated for analyses. Prior to
MS, samples were quality-controlled by SDS–PAGE and silver stain-
ing to ensure efficient removal of non-cross-linked material had
occurred (Fig 1B).
Label-free proteomic analyses of the FN + VEGF, FN, and PLL
adhesomes (Fig 1C; Table EV1) initially detected and quantified
1,468 proteins. Stringent filtering, requiring proteins to be detected
in all three repeats of at least one condition, left 1,064 proteins—a
high confidence dataset that was used to define the endothelial
adhesome. Hierarchical clustering based on average Euclidian
distance identified 12 clusters (A–L), which could be considered
VEGF-enriched (A–C), FN-enriched (D–F) and PLL-enriched (G–L)
proteins. Fisher’s exact test enrichment analysis was carried out to
identify which pathway, process or component proteins within these
clusters belong to using Gene Ontology annotations. Cell projection
(GOCC, P = 8.62 9 105) and microtubule (GOCC, P = 1.6 9 104)
categories were significantly enriched when cells were treated with
growth factor, suggesting they are important in VEGF-mediated
processes. Leucocyte trans-endothelial migration (KEGG,
P = 9.71 9 105) proteins were enriched in the FN adhesome, but
not in the VEGF-stimulated adhesome, suggesting our cells repre-
sent quiescent vasculature without VEGF stimulation. This same
category contains many endothelial-specific proteins (e.g. VE-
cadherin, Cdh5), further confirming that the cells have an endothe-
lial identity. Focal adhesion (KEGG, P = 9.31 9 107) proteins were
enriched in the FN adhesome but depleted in the PLL adhesome,
confirming the success of the adhesome enrichment process, MS
and downstream analysis. Other adhesion/migration-associated
categories, focal adhesion (GOCC, P = 5.99 9 105), cell projection
(GOCC, P = 3.03 9 105), cell adhesion (GOBP, P = 1.61 9 106)
and lamellipodium (GOCC, P = 1.38 9 104), were depleted in the
PLL adhesome.
To test the consequences of excluding b3-integrin from the EC
adhesome, we decided to profile changes in b3-heterozygous
(b3HET) ECs, which carry one wild-type allele of b3-integrin and
one knockout allele. These cells express 50% wild-type levels of b3-
integrin. As in previous studies, we decided to use b3HET cells for
these initial analyses, rather than b3-integrin knockout (b3NULL)
cells, hypothesising this would circumvent potential developmental
changes arising from the complete loss of the protein, which we felt
might confound quantitative interpretations of the EC adhesome; we
have shown these cells are a good model for studying the role of
avb3-integrin in cell migration, whilst evading changes arising from
the complete loss of the integrin on both alleles (e.g. up-regulated
total VEGFR2 expression) [17]. Both wild-type (b3WT) and b3HET
ECs adhere equally to saturating concentrations (10 lg ml1) of FN
(see Ellison et al [17]). To compare the size distribution of FAs
between b3WT and b3HET ECs (which might affect the stoichiome-
try of components in the adhesome), we seeded cells for 90 min on
FN, immunostained for paxillin, and measured FA area; we noted
no differences in the percentage of FA size distributions between the
two genotypes (Fig 2A). Therefore, MS analyses comparing the
adhesome between b3WT and b3HET ECs were performed (Fig 2B;
Table EV2). Enrichment analysis showed a depletion of cytoskeletal
components (GOCC, P = 4.73 9 105) in the b3WT adhesome when
compared with the b3HET adhesome, despite the enrichment of
adhesion/migration-associated categories previously noted in the
FN adhesome of b3WT ECs (Fig 1C). Whilst a majority of individual
FA components in the mature adhesome do not change upon b3-
integrin depletion, downstream connections to cytoskeletal compo-
nents do. We took a particular interest in microtubules (MTs)
because by SAM analysis all detected tubulins were significantly up-
regulated in the b3HET adhesome. To confirm this finding by other
means, we probed Western blots for a-tubulin and showed a signifi-
cant increase in FA-enriched samples from b3HET cells compared
with b3WT cells (Fig 2C).
Our findings intimated that avb3-integrin drives MT localisation
away from FAs. To increase the power of our downstream mecha-
nistic analyses, we felt it was appropriate to now also include
b3NULL ECs in our studies. We examined MT organisation in
b3WT, b3HET and b3NULL ECs by immunolabelling for a-tubulin
in whole cells (Fig 3A). No gross changes in cell microtubule
arrays were observed. Furthermore, total cellular levels of a-
tubulin were similar across all three genotypes (Fig 3B). However,
co-localisation of MTs at peripheral FAs was greater in b3HET and
b3NULL ECs, compared to b3WT ECs, as was extension into
▸Figure 1. Defining the FN endothelial adhesome.A WT ECs were adhered to fibronectin- (top row) or poly-L-lysine (bottom row)-coated coverslips for 90 min before fixing and immunostaining for neuropilin-1 (Nrp1,
green) and talin-1 (Tln1, red) along with a nuclear stain (DAPI, blue). Scale bar = 10 lm.
B An example silver stain used in the quality control of adhesome samples. Adhesome enrichment was carried out on 6 9 106 WT ECs on fibronectin (FN), fibronectin
with VEGF (FN + VEGF) or poly-L-lysine (PLL) before acetone precipitation. After resuspension, samples were run on a SDS–PAGE gel along with a whole cell lysate
control and silver-stained.
C Triplicate adhesome samples from WT ECs adhered on fibronectin (FN), fibronectin with VEGF (FN + VEGF) or poly-L-lysine were sent for quantitative mass spec
analysis. Label-free quantification was carried out using MaxQuant followed by analysis in Perseus. Unsupervised hierarchical clustering (Euclidian distance
calculation) was carried out with red showing highly abundant proteins and green showing low abundance proteins. Twelve significant clusters were automatically
identified using a distance threshold of 3.34 and labelled as A–L. Angiogenesis-associated proteins were identified using GOBP annotations (GO:0001525, GO:0002040,
GO:0002042, GO:0016525, GO:0045765, GO:0045766) and are displayed in the table along with their associated cluster.
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lamellipodia (Fig 3C; for an example of quantification of the latter,
see Fig EV1). Overall, the findings suggest that b3-integrin limits
the targeting of MTs to FAs.
Given that MTs can drive FA turnover and thus cell migration
[18], we next tested whether EC migration is differentially sensitive
to microtubule targeting agents (MTAs) in b3HET and b3NULL ECs.
A
B C
Figure 1.
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Figure 2. Analysis of the b3-integrin-dependent adhesome.
A Distribution of adhesion size classes (0–2 lm; 2–10 lm; > 10 lm) in b3WT versus b3HET endothelial cells (n = 1,400 FAs per genotype, from two independent
experiments).
B Visual representation of the significance analysis of microarrays (SAM) method as a volcano plot for b3WT and b3HET samples (n = 3). t-Test difference is plotted
against log of the P-value. The blue lines show the cut-off for significance as defined by the SAM. Integrin-b3 (Itgb3) as well as all detected tubulins (Tub) have been
highlighted as red points.
C Adhesome samples from b3WT and b3HET endothelial cells adhered to fibronectin. Samples were Western-blotted for integrin-b3 (Itgb3), a-tubulin and heat-shock
protein 70 (Hspa1a). Blot shown is representative of the five individual experiments that are quantified in the bar graph below. Bars = mean (SEM) relative
a-tubulin levels normalised to Hspa1a levels. Significant differences between means were evaluated by unpaired two-tailed Student’s t-test.
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For each MTA examined, we first determined the dose of the
compound that allowed 90% survival of b3WT ECs (see Materials
and Methods) and then tested the effects of this dose on random
migration in b3WT, b3HET and b3NULL cells (Fig 3D; raw migration
data shown in Fig EV2). Random migration was affected by MT
stabilisers (Paclitaxel, Epothilone B) in cells of all three genotypes,
However, b3WT ECs were insensitive to the MT destabilisers tested
(Colchicine, Mebendazole, Fosbretabulin) and the mechanistically
unique MTA Eribulin (which functions through an end poisoning
mechanism [19]), whilst b3HET and b3NULL ECs generally showed a
sensitivity to all classes of compounds tested. We extended these
types of analyses in vivo to examine the effects of Eribulin and
Fosbretabulin on tumour growth and angiogenesis. We chose these
two MTAs as they are well tolerated in mice [20,21] and used clini-
cally in humans. We settled on suboptimal doses (see Materials and
Methods) that would allow us to observe potential synergy with
endothelial depletion of b3-integrin. b3-integrin-floxed/floxed mice
[22] were bred with Tie1Cre mice [23] to generate b3-integrin-floxed/
floxed Cre-positive animals (Cre-negative littermates were used as
controls). CMT19T lung carcinoma cells were injected subcuta-
neously and allowed to establish for 7 days, at which point the MTAs
were administered (see Materials and Methods for dosing regimes).
Neither Eribulin nor Fosbretabulin had any effect on tumour growth
in Cre-negative animals compared with vehicle-treated animals,
but tumour growth was reduced in MTA-treated Cre-positive
animals (Fig 3E). Analysis of tumours by immunostaining for
blood vessels showed a reduction in intratumoral microvascular
density only in sections from MTA-treated Cre-positive animals
(Fig 3F). These studies suggested that the loss of endothelial b3-
integrin sensitises angiogenic responses to MT destabilisers both
in vitro and in vivo.
The increased sensitivity to destabilising MTAs suggested to us
that there is an increased population of stable MTs in b3HET and
b3NULL ECs compared with their wild-type counterparts. We
explored this premise by exposing ECs to cold temperatures (which
destabilises MTs), washing out tubulin monomers [24], followed by
immunolabelling for a-tubulin. We noted elevated stable MTs in
both b3HET and b3NULL cells (Fig 4A). Re-introducing b3-integrin
into b3NULL cells restored MT sensitivity to cold; MTs were more
sensitive to cold treatment in NULL cells expressing full-length
human b3-integrin, than MTs in cells transfected with an empty
vector control (Fig EV3). We also measured MT stability biochemi-
cally by extracting both cold-sensitive and cold-stable MTs from the
same sample of cold-treated cells and Western blotting for a-tubulin
(Fig 4B). On whole, b3HET and b3NULL ECs showed decreased
cold-sensitive and increased cold-stable MTs compared with b3WT
ECs.
To gain further mechanistic insight into how b3-integrin at FAs
might be regulating MT function, we delved deeper into our b3-
dependent adhesome data. We noted that Rcc2 clusters with b3-
integrin in the b3WT adhesome, but is significantly decreased in
that of b3HET ECs. Rcc2 (also known as telophase disc protein of
60 kDa, TD-60) has previously been shown to associate with inte-
grin complexes [25] and to regulate MTs [26]. We therefore exam-
ined whether Rcc2 was regulating MT stability in ECs. Knocking
down Rcc2 by siRNA in b3WT ECs elicited a significant increase in
cold-stable MTs (Fig 5A; see Fig EV4 for representative MT stain-
ing). This finding suggested to us that Rcc2 plays a b3-dependent
role in regulating MTs in ECs, but does not do so in isolation.
We therefore cross-referenced our adhesome data with an Rcc2 pull-
down assay performed from HEK-293T cells (Table EV3) [27]. Some
obvious potential candidates (e.g. Coronin-1C) were present in both
the b3WT and b3HET adhesomes, but at the same level, so were
ruled out from further analysis. However, annexin-a2 (Anxa2) co-
precipitates with Rcc2 in HEK-293T cells and, like Rcc2, was
reduced in the b3HET adhesome. Therefore, we examined whether
Anxa2 was also regulating MT stability in ECs via siRNA-mediated
knockdown. Like Rcc2 knockdown, even a relatively small (~ 30%)
Anxa2 knockdown in b3WT ECs elicited a significant increase in
cold-stable MTs (Fig 5B; see Fig EV4 for representative MT
▸Figure 3. Analysis of microtubules in b3WT, b3HET and b3NULL endothelial cells.A b3WT, b3HET and b3NULL endothelial cells were adhered to fibronectin-coated coverslips for 90 min before being PHEMO fixed and immunostained for a-tubulin
(green). Nuclear (DAPI, blue) and phalloidin (F-actin, red) stains were also used. Inverted black and white images of a-tubulin and F-actin are shown below the three-
colour overlays. Scale bar = 10 lm.
B b3WT, b3HET and b3NULL endothelial cells were adhered to fibronectin for 90 min before being lysed and Western-blotted for integrin-b3 (Itgb3), a-tubulin and
Gapdh (as a loading control).
C Left: b3WT, b3HET and b3NULL endothelial cells were adhered to fibronectin-coated coverslips for 90 min before being methanol (20°C) fixed and immunostained
for a-tubulin and talin-1. The number of microtubules that terminated (overlapping staining) at a talin-1 containing focal adhesion was counted for each genotype
(n = 15 cells per genotype, from three independent experiments). Right: b3 WT, HET and NULL ECS were transfected with paxillin-GFP and left to recover overnight.
The cells were then adhered to fibronectin-coated coverslips and allowed to recover for 3 h before being treated with 100 nM SiRTubulin and 1 lM verapamil
overnight. The next day, fresh media containing SiRTubulin and verapamil (same dose) were added and cells were imaged every minute for 30 min (n = 3 cells per
genotype, from three independent experiments). Areas of adhesive fronts were assessed by measuring the growth of paxillin–GFP-positive areas between the 1st and
30th image. The number of microtubules that entered the adhesive front was quantified to give the number of microtubules entering lamellipodia relative to the area
of adhesive fronts for each cell. Significant differences between means were evaluated by unpaired two-tailed Student’s t-test. Error bars are SEM.
D b3WT, b3HET and b3NULL endothelial cells were adhered to fibronectin overnight. Migration speed of individual cells was measured over 15 h using the MTrackJ
plugin for ImageJ under the influence of the indicated MTA. Migration speeds are shown as a percentage of the speed of the corresponding genotype under DMSO
(vehicle) treatment (n ≥ 46 cells per genotype, from four independent experiments). Significant differences between means were evaluated by unpaired two-tailed
Student’s t-test. Error bars are SEM.
E b3flox/flox Tie1Cre-positive (pos) and Cre-negative (neg) animals were injected subcutaneously with 1 9 106 CMT19T lung carcinoma cells and then treated with
vehicle (veh), or Eribulin (Eri). Bar graph shows mean (SEM) tumour volumes (n ≥ 6; from two to three independent experiments for each treatment condition) at
the end of the experiment. Micrographs (below) show representative tumours. Scale bars = 5 mm.
F After excision, tumours from b3flox/flox Tie1Cre-positive (pos) and Cre-negative (neg) animals were processed and CD31 staining was assessed in vessel hot spots (see
Materials and Methods) to measure vascular density. Bars = mean (SEM) vessel number per mm2 (n = 5 sections from each genotype, taken over two to three
independent experiments for each treatment condition). Micrographs (below) show representative images of sections stained for alpha-smooth muscle actin (aSMA,
green), CD31 (red), DAPI (blue). Dotted white line indicates border of tumour and surrounding connective tissue. Scale bars = 100 lm.
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Figure 4. Analysis of microtubule stability in b3WT, b3HET and b3NULL endothelial cells.
A Top: b3WT, b3HET and b3NULL endothelial cells were adhered to fibronectin-coated coverslips for 75 min at 37°C before being moved to ice for 15 min. Soluble
tubulin was then washed out using PEM buffer (see Materials and Methods) before fixing with 20°C methanol (Note: this protocol leads to nuclear auto-fluorescent
background in all three channels used). Immunostaining was carried out for a-tubulin (green) and talin-1 (Tln1, red). DAPI (blue) was used as a nuclear stain. Images
shown are representative of the data shown in the bar graph shown below. Scale bar = 5 lm. Bottom: Dot plots = mean (SEM) number of cold-stable microtubules
per cell (n ≥ 300 cells per genotype, from three independent experiments). Significant differences between means were evaluated by unpaired two-tailed Student’s
t-test.
B b3WT, b3HET and b3NULL endothelial cells were adhered to fibronectin for 75 min at 37°C before being moved to ice for 15 min. Cold-soluble tubulin (left blot) was
then washed out using PEM buffer and Western-blotted for a-tubulin and Gapdh (as a loading control). Cold-insoluble tubulin (middle blot) from the same cells was
obtained by lysing the remaining cells and Western blotting for a-tubulin and Gapdh (as a loading control). Right bar chart: Bars = mean (SEM) relative cold-soluble
and cold-insoluble a-tubulin levels for each genotype. Data are representative of four independent experiments. *indicates statistical significance compared to WT
(P < 0.05). Significant differences between means were evaluated by unpaired two-tailed Student’s t-test.
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staining). Moreover, a double knockdown of both targets led to an
additive increase in cold-stable MTs in b3WT ECs (Fig EV4).
Both Rcc2 [25,27] and Anxa2 [28] have been identified as regula-
tors of Rac1, and work by a number of groups has demonstrated that
cortical Rac1 activity promotes MT stability [29–31]. Because total
Rac1 stoichiometry was unchanged when comparing b3WT and
b3HET EC adhesomes, we hypothesised that Rcc2/Anxa2-dependent
alterations in Rac1 activity were responsible for altered MT stability
in b3HET and b3NULL ECs. First, we tested the premise that Rac1
plays a differential role in regulating MT stability in b3WT and
b3-depleted ECs by testing the effects of the Rac1 inhibitor
NSC23766. NSC23766 had no effect on MT stability in b3WT cells,
but the number of cold-stable MTs in both b3HET and b3NULL ECs
was reduced in the presence of the inhibitor (Fig 5C; see Fig EV4 for
representative MT staining). We also demonstrated that the increases
observed in MT stability upon Rcc2 or Anxa2 knockdown were abro-
gated in the presence of NSC23766 (Fig EV5), suggesting that both
proteins regulate MT stability in ECs in a Rac1-dependent manner.
Rcc2 has previously been reported to limit the activation of both
Rac1 and Arf6 [25]. Indeed, Rcc2 can guide mesenchymal cell
migration by trafficking Rac1 and controlling its exposure to GEFs
[27]. We therefore tested whether there were differences in Rcc2/
Anxa2/active-Rac1 associations between b3WT and b3-depleted
ECs. First, we examined total cellular levels or Rac1 and showed
they were equivalent in all three cell lines (Fig 5D). PAK-PBD pull-
downs of GTP-bound Rac1 showed co-association of all three
proteins in b3WT, b3HET and b3NULL ECs (Fig 5E), so we
concluded that changes in Rac1 activity alone were not responsible
for alterations in MT stability in b3-depleted cells. Humphries et al
[25] showed that Rcc2 is recruited to a5b1-FN complexes but not
a4b1-Vcam1 (vascular cell adhesion molecule-1) complexes in cells
expressing both a4- and a5-integrins. Thus, we also tested
associations between Rcc2, Anxa2 and a5-integrin in b3WT and b3-
depleted ECs by PAK-PBD pull-downs. Rcc2, Anxa2, b3-integrin and
a5-integrin were pulled down with Rac1-GTP in b3WT ECs. Rcc2
and Anxa2 were also pulled down with Rac1-GTP in b3HET and
b3NULL ECS, whilst b3-integrin-Rac1-GTP associations were lost
and a5-integrin-Rac1-GTP associations were increased (Fig 5E).
Given the stoichiometry of a5-integrin in the b3-depleted adhesome
is unchanged compared to the b3WT adhesome (Fig 2) whilst Rcc2
and Anxa2 levels are decreased, we speculated that a substantial
proportion of the observed increase in Rcc2/Anxa2/active-Rac1/
Itga5 associations in b3-depleted cells occur away from b3-rich FAs,
perhaps in recycling endosomes. Endocytic trafficking of Rac1 is
required for the spatial restriction of signalling during mammalian
cell migration [32]. In support of this hypothesis, we demonstrated
a redistribution of Rac1-GTP in b3-depleted ECs using a Raichu-
Rac1 biosensor (Fig 5F); compared to b3WT ECs, a substantial
proportion of active Rac1 in b3HET and b3NULL cells appeared
cytoplasmic. This redistribution of active Rac1 appeared to be inde-
pendent of the total level of active Rac1 present in the cells; active
Rac1 levels were only noticeably elevated in b3HET cells (Fig 5F).
By mining the FN-b3-integrin EC adhesome, not only we have
generated a valuable tool for the integrin and angiogenesis commu-
nities, but also we have utilised the data to uncover a novel role for
b3-integrin in regulating MT function/stability during EC migration.
We previously showed that endothelial Rac1 is only required for
tumour growth and angiogenesis when b3-integrin is absent [33],
but the underlying mechanism for this observation has remained
unclear. Our working hypothesis is that engagement of avb3-
integrin with FN at mature FAs localises an Rcc2/Anxa2/Rac1
containing complex to these sites, either preventing GTP-Rac1 from
participating in MT stability or actively destabilising MTs (our
experiments do not allow us to distinguish between these two
▸Figure 5. Microtubule stability in endothelial cells is regulated by Itgb3, Rcc2, Anxa2 and Rac1.A b3WT ECs were transfected with control pool (CP) or Rcc2 smart pool siRNA and allowed to recover for 48 h. They were then adhered to fibronectin-coated coverslips
for 75 min at 37°C before being moved to ice for 15 min. Soluble tubulin was then washed out using PEM buffer before fixing with 20°C methanol. Immunostaining
was carried out for a-tubulin to allow counting of the number of cold-stable microtubules per cell. Left: Western blot showing representative Rcc2 knockdown. Gapdh
is shown as a loading control. Right: Bars = mean (SEM) number of cold-stable microtubules shown as a percentage relative to CP-treated cells (n ≥ 455 cells per
condition, from three independent experiments). Significant differences between means were evaluated by unpaired two-tailed Student’s t-test.
B b3WT ECs were transfected with control pool (CP) or Anxa2 smart pool siRNA and allowed to recover for 48 h. They were then adhered to fibronectin-coated
coverslips for 75 min at 37°C before being moved to ice for 15 min. Soluble tubulin was then washed out using PEM buffer before fixing with 20°C methanol.
Immunostaining was carried out for a-tubulin to allow counting of the number of cold-stable microtubules per cell. Top: Western blot showing representative Anxa2
knockdown in three separate samples. Bottom left: Bars = mean (SEM) Anxa2 knockdown shown as a percentage relative to CP-treated cells. Samples have been
normalised to Hspa1a. Bottom right: Bars = mean (SEM) number of cold-stable microtubules shown as a percentage relative to CP-treated cells (n ≥ 450 cells per
condition, from three independent experiments). Significant differences between means were evaluated by unpaired two-tailed Student’s t-test. The graph is
representative of 3 independent experiments.
C b3WT, b3HET and b3NULL endothelial cells were adhered to fibronectin-coated coverslips for 60 min at 37°C before being treated with DMSO (control) or 50 lM
NSC23766 and incubated at 37°C for a further 15 min. Coverslips were moved to ice for 15 min. Soluble tubulin was then washed out using PEM buffer before fixing
with 20°C methanol. Immunostaining was carried out for alpha-tubulin to allow counting of the number of cold-stable microtubules per cell. Bars = mean (SEM)
number of microtubules per cell shown as a percentage relative to DMSO-treated controls (n = 218 cells per condition, from two independent experiments).
D b3WT, b3HET and b3NULL endothelial cells were adhered to fibronectin for 90 min before being lysed and Western-blotted for integrin-b3 (Itgb3), Rac1 and Hspa1a
(as a loading control). Blot shown is representative of three individual experiments.
E b3WT, b3HET and b3NULL endothelial cells were adhered to fibronectin-coated plates for 90 min before being lysed in MLB (see Materials and Methods). GTP-Rac1
and bound proteins were extracted from cleared MLB using PAK-1 PBD magnetic beads at 4°C for an hour before being Western-blotted for Itga5, Itgb3, Rcc2, Anxa2
and Rac1. Blot is representative of at least three independent experiments Right: Bars = mean (SD) level of association of the indicated protein with GTP-Rac1,
shown relative to b3WT associations (and normalised to the level of active Rac1 pulled down). Results are from at least three independent experiments. Significant
differences between means were evaluated by unpaired two-tailed Student’s t-test.
F b3WT, b3HET and b3NULL endothelial cells were transfected with a Raichu-Rac1 biosensor. After 48 h, cells were adhered to fibronectin-coated plates for 90 min and
then fixed in PFA. Left: FRET efficiency was measured as described in Materials and Methods. Graph shows mean FRET efficiencies (SEM; n = 17 cells per genotype,
from two independent experiments). Right: Representative images showing spatial distribution of Rac1 FRET efficiency in b3WT, b3HET and b3NULL endothelial cells
(white stars indicate cytoplasmic localisation of active Rac1 in b3HET and b3NULL). Scale bar = 5 lm.
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possibilities), perhaps by controlling its exposure to GEFs. When
avb3 is not present, the complex associates with a5b1-integrin
instead, where it now has the opposite effect on MTs (see synopsis).
This re-positioning of Rac1 activity means that it plays a role in MT-
linked EC migration only when avb3 is not present in mature FAs.
There is certainly precedence for b3-integrin regulating spatial distri-
bution of signalling pathway components in cells. For example, we
previously showed that b3-integrin plays a role in locally suppress-
ing b1-integrin in fibroblasts to promote persistent cell protrusion
and migration by regulating interactions between vasodilator-stimu-
lated phosphoprotein (Vasp) and Rap1-GTP-interacting adaptor
molecule (Apbb1ip/RIAM) [34]. Moreover, MTs have recently been
shown to target active b1-integrins [35]. Thus, it will be particularly
pertinent to next determine the full composition of the Rcc2/Anxa2/
Rac1-GTP complex as many of the proteins that might be suspected
to play a role in MT capture (e.g. Clip170 and Clasps) do not appear
to be present in the EC adhesome [36]; to gain a full picture of how
MT stability/FA targeting is regulated in ECs, it will also be essential
to establish how this complex behaves in a5b1-deficient ECs.
Finally, it is worth considering how changes in levels of integrin
expression might affect the cellular responses we have examined.
Whilst, in general (e.g. sensitivity to MTAs, including cold), b3HET
and b3NULL cells behaved similarly in the assays we employed,
there are two notable differences: (i) b3NULL cells showed
increased MT targeting to lamellipodia, compared to b3HET cells
(Fig 3C), which might suggest altered MT dynamics between the
two genotypes. It will be important to examine microtubule dynam-
ics in greater detail (e.g. rates of growth, catastrophe and rescue)
with changes in integrin expression patterns/levels. (ii) On fibro-
nectin, b3HET cells showed increased Rac1-GTP levels compared to
b3NULL cells (Fig 5). This might relate to the increased total
VEGFR2 levels noted in b3NULL [37] but not b3HET [17] cells. If
VEGFR2 is playing a role here, we speculate it is separate from its
known interactions with avb3-integrin. VEGFR2 and avb3-integrin
interactions are augmented on vitronectin [38], and we do not
detect VEGFR2 in our FN-dependent EC adhesome (Fig 1). Notwith-
standing, our findings suggest that once effective avb3-integrin
antagonists are available (e.g. ProAgio [39]), they may be particu-
larly useful as anti-angiogenic agents when used in combination
with already approved MTAs, such as Eribulin.
Materials and Methods
Reagents
Unless otherwise stated, all chemicals used were purchased
from Sigma-Aldrich (Poole, UK). Vascular endothelial growth
factor (mouse VEGF-A164) was made in house according to Krilleke
et al [40].
Animals
All animals were on a mixed C57BL6/129 background. Littermate
controls were used for all in vivo experiments. All animal experiments
were performed in accordance with UK Home Office regulations and
the European Legal Framework for the Protection of Animals used for
Scientific Purposes (European Directive 86/609/EEC).
Mouse endothelial cell isolation and culture
Mouse lung ECs were isolated from adult mice on a mixed C57BL6/
129 background as per Reynolds and Hodivala-dilke [41] and then
subsequently immortalised and cultured as per Ellison et al [17].
The cell lines used in the studies presented here were cross-refer-
enced to a pure C57BL6 genetic background via a 384 single nucleo-
tide polymorphism panel (Charles River Genetic Testing Services,
Wilmington, MA, USA). These analyses showed the following:
b3WT = 91.99% C57BL6; b3HET = 93.03% C57BL6; b3NULL =
44.75% C57BL6.
Adhesion assay
Ninety-six-well plates were coated in 10 lg ml1 fibronectin (FN) in
phosphate buffered saline (PBS) overnight at 4°C and then blocked
with 1% bovine serum albumin (BSA) in PBS for 1 h at room
temperature. A total of 20,000 cells were seeded into each well and
allowed to adhere for 90 min. Cells were then washed with PBS
with 1 mM MgCl2 and 1 mM CaCl2 three times to remove non-
adherent cells and fixed with 4% paraformaldehyde (PFA) for
10 min at room temperature. After a further PBS wash, cells were
stained with 1% methylene blue in 10 mM borate buffer pH 8.5/
50% methanol for 30 min at room temperature. Excess stain was
removed with RO water before a 50% 0.1 M HCl/50% ethanol
destain solution was used for 10 min at room temperature. The
destain solution was then moved to a new plate, and absorbance
was measured at 630 nm.
Focal adhesion enrichment
Focal adhesion enrichment was carried out as described in Ellison
et al [17] and Schiller et al [13]. A small amount of each focal adhe-
sion sample generated was quality-controlled by running a 10%
SDS–PAGE gel followed by silver staining (PierceTM Silver Stain Kit,
Thermo Fisher Scientific, Cramlington, UK). Good-quality samples
were then analysed by Western blotting or mass spectrometry.
Mass spectrometry (MS)
Mass spectrometry was carried out by the Fingerprints Proteomics
Facility (Dundee University, Dundee, UK) as per Schiller et al [13].
Peptides were identified and quantified using MaxQuant [42] soft-
ware using the Andromeda peptide database. To achieve label-free
quantitative results, three biological repeats were pooled and each
of these pooled samples was analysed via three technical repeats
through the spectrometer.
MS statistical analysis
All mass spec analysis was performed using the Perseus [43] bioin-
formatics toolbox for MaxQuant. Statistical significance was identi-
fied using the significance analysis of microarrays (SAM) method
[44]. Unsupervised hierarchical clustering was performed using
Perseus’ built in tools. KEGG and GO annotations were obtained
from the mouse annotations package via Perseus (downloaded 20/
06/2015) and used to identify angiogenesis, cytoskeleton and focal
adhesion-related genes.
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Random migration
Twenty-four-well plates were coated with 10 lg ml1 FN in PBS
overnight at 4°C and then blocked with 1% BSA for 1 h at room
temperature. A total of 10,000 ECs were seeded per well and
allowed to recover overnight. Media were then replaced with media
containing one of the following microtubule targeting agents (MTAs
—from Abcam, Abingdon, UK, unless otherwise noted): Paclitaxel
5 nM, Epothilone B 1 nM, Colchicine 10 lM, Mebendazole 0.4 lM,
Fosbretabulin 0.5 lM or Eribulin 1 lM (a kind gift from Katherine
Weilbaecher, Washington University, MO, USA); DMSO was used
as a vehicle control. A phase contrast image was taken of each well
every 20 min using an inverted Axiovert (Zeiss) microscope for
15 h at 37°C and 5% CO2. The ImageJ plugin MTrackJ [45] was
then used to manually track individual cells, and the speed of
random migration was calculated.
Microtubule stability assays
Microtubule cold stability assays were carried out as described in
Ochoa et al [24]. Briefly, 750,000 ECs were seeded per well of a six-
well plate (FN-coated/BSA-blocked as described earlier) and
allowed to adhere for 75 min at 37°C before being moved to ice for
15 min. Cells were washed with PBS and then 100 ll of PEM buffer
(80 lM PIPES pH 6.8, 1 mM EGTA, 1 mM MgCl2, 0.5% Triton
X-100 and 25% (w/v) glycerol) for 3 min. A second brief wash was
performed with 50 ll PEM buffer. All PEM buffer was collected and
pooled together with 150 ll EB buffer (3% SDS, 60 mM Sucrose,
65 mM Tris–HCL pH 6.8) at 29 concentration (representing
cold-soluble microtubules). Remaining material on the plate was
then extracted using 300 ll of EB buffer (representing cold-stable
microtubules). Samples were then used in Western blotting
analysis.
Additionally, the same procedure was used on ECs adhered to
FN-coated/BSA-blocked coverslips (acid washed and bake-sterilised
before coating). They were treated as above except that after PEM
washing, the slides were immediately immersed in 20°C 100%
methanol for 20 min. Coverslips were then used in immunolabelling
analysis.
In vivo tumour growth assays
The syngeneic mouse lung carcinoma cell line (derived from
C57BL6 mice) CMT19T was used to grow subcutaneous tumours in
b3 fl/fl Tie1Cre-positive (and Cre-negative littermate control) mice.
Under anaesthetic, mice were injected subcutaneously in the flank
with 1 9 106 cells. Tumours then grew for 7 days, at which point
they were palpable through the skin, before the mice were treated
with: (i) 0.15 mg kg1 Eribulin (kindly provided by Katherine Weil-
baecher, Washington, USA) intravenously once a week for 2 weeks;
or (ii) 50 mg kg1 Fosbretabulin intraperitoneally every 4 days.
After 21 days, mice were culled and tumours were excised, photo-
graphed and measured for volume using a digital calliper. Tumours
were bisected along the midline, fixed overnight in 4%
paraformaldehyde, preserved for several days in cryoprotectant
(20% sucrose, 2% poly(vinylpyrrolidone) in PBS), embedded in
gelatine (8% gelatine, 20% sucrose, 2% poly(vinylpyrrolidone) in
PBS) before being snap-frozen and stored at 80°C.
Focal adhesion and microtubule tracking
1 9 106 ECs were transfected with a GFP-tagged paxillin cDNA
expression construct (provided by Maddy Parsons, KCL) by nucleo-
fection. Cells were allowed to recover overnight before a fraction
was seeded on FN-coated/BSA-blocked coverslips (acid washed and
baked before coating) and adhered for 3 h. Cells were then treated
with 100 nM SiRTubulin (Cytoskeleton Inc CY-SC002) and 1 lM
Verapamil overnight. Coverslips were imaged individually on an
Axiovert (Zeiss) inverted microscope where one image of a GFP-
positive cell was taken every minute for 30 min at 37°C and 5% CO2
in green and far-red channels. During imaging, media were replaced
with Phenol red-free OptiMEM + 2% FBS containing 100 nM
SiRTubulin and 1 lM Verapamil. The total area of adhesive fronts
was assessed by measuring the growth of paxillin–GFP-positive areas
between the 1st and 30th image, and then, the number of micro-
tubules that entered the adhesive front over 30 min was counted.
Western blotting
For Western blot analysis of total tubulin levels, ECs were seeded at
750,000 per well of a FN-coated/BSA-blocked six-well plate and
allowed to adhere for 90 min before being lysed in EB buffer. For
the microtubule stability assay and focal adhesion enrichment,
samples were prepared as above. 20 lg from each sample was
loaded onto 10% polyacrylamide gels and then transferred to a
nitrocellulose membrane and incubated for 1 h in 5% milk powder
in PBS with 0.1% Tween 20 (PBSTw), followed by overnight incu-
bation in primary antibody diluted 1:1,000 in 5% BSA in PBSTw at
4°C. Primaries used were against integrin beta 3 (Cell Signalling
4702), alpha-tubulin (Abcam 7291), Gapdh (Abcam 9484), Rcc2
(Abcam 70788), Hspa1a (clone B-6 Santa Cruz Biotechnology),
Anxa2 (Abcam 41803) and Itga5 (Cell Signalling 4705). The
membranes were then incubated with the appropriate horseradish
peroxidase (HRP)-conjugated secondary antibody (Dako) diluted
1:2,000 in 5% milk in PBSTw for 1 h at room temperature. The blot
was visualised using Piece ECL Western Blotting Substrate Kit
(Thermo Fisher) and chemiluminescence detected on a Fujifilm
LAS-3000 darkroom (Fujifilm UK Ltd, Bedford, UK).
Immunolabelling cells
A total of 20,000 ECs were seeded onto FN-coated/BSA-blocked
coverslips and adhered for 90 min before being washed with PBS and
immersed in 20°C methanol for 20 min. Alternatively, cells were
prepared as per the microtubule stability assay protocol described
above. Coverslips were then washed with PBS, blocked for 10 min at
room temperature with 0.5% BSA, 1% goat serum in PBS with 0.25%
Triton X-100 and incubated with primary antibody diluted 1:250 in
PBS for 1 h at room temperature. After subsequent PBS washes, the
coverslips were incubated with Alexa Fluor-conjugated secondary
antibodies raised in donkey (Fisher Scientific) diluted 1:500 in PBS.
Coverslips were washed again in PBS before being mounted onto
slides using Prolong Gold with DAPI (Fisher Scientific). Primaries
used were anti-alpha-tubulin (Abcam 52866), anti-paxillin (Abcam
32084) anti-talin (Sigma T3287) and anti-Nrp1 (R&D Systems AF566).
To quantify microtubule targeting focal adhesions, images were
taken of stained cells using an epifluorescent microtubule, and then,
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the number of microtubules with an end overlapping with a focal
adhesion was counted for each cell.
Simultaneous phalloidin (Thermo Fisher A12380) and alpha-
tubulin staining were carried out using PHEMO fixation [46].
Immunolabelling tissue sections
Five-micrometer cryosections were prepared from frozen tumours
and stained as described previously [17]. Primaries used were anti-
CD31 (R&D Systems AF3628, 1:500) and alpha-smooth muscle actin
(Abcam 5694; 1:1,000). Images were acquired on an Axioplan
(Zeiss) epifluorescent microscope. Vessel density (immediately adja-
cent to, but not including, the tumour border) was measured by
hand in three hot spots per section. The area of each counted region
was calculated using ImageJ.
siRNA knockdown
Knockdowns of Rcc2 and Anxa2 were achieved using 3 lg of Dhar-
macon ON-TARGETplus SMARTpool siRNA (control smart pool
used as knockdown control) per 1 9 106 ECs in an Amaxa Nucleo-
fector II (T-005 setting). Cells were allowed to recover for 48 h to
allow knockdown to take effect.
Generation of human b3 integrin expressing cells
1 9 106 b3NULL endothelial cells were transfected with 10 lg of
MfeI (New England Biolabs, Hitchin, UK) linearised full-length
human b3-integrin (see Robinson et al [47]) cloned into pcDNATM
6.2/C-EmGFP (see Amaxa nucleofection above). An empty vector
(EV) was used as a control. Forty-eight hours post-transfection cells
were selected with 10 lg ml1 of blasticidin (Thermo Fisher). Cells
surviving 2 weeks were analysed for b3-integrin expression by
Western blotting.
Active Rac1 pull-down
6 9 106 ECs were seeded onto FN-coated/BSA-blocked (as
described above) 10-cm plates and allowed to adhere for 90 min.
Rac1 Activation Magnetic Beads Pull-down Assay Kit (Millipore 17-
10393) was then used per manufacturer’s instructions. Pull-down
material was then loaded directly onto a gel for Western blotting.
Rac1 biosensor analyses
1 9 106 ECs were transfected with 10 lg of Raichu-1011X (a gift
from Maddy Parsons, KCL) via an Amaxa Nucleofector II (T-005
setting). Cells were allowed to recover for 48 h and then plated onto
FN-coated/BSA-blocked (as described above) coverslips for 90 min.
Cells were fixed for 10 min in 4% PFA and then mounted in Prolong
Gold without DAPI (Thermo Fisher).
Samples for analysis of the Rac FRET biosensor by acceptor
photobleaching were imaged and analysed as previously described
[48]. Briefly, images were acquired using an inverted Nikon A1R
laser scanning confocal microscope. The CFP and YFP channels
were excited using the 440-nm diode laser and the 514-nm argon
line, respectively. The two emission channels were split using a
545-nm dichroic mirror, which was followed by a 475- to 525-nm
bandpass filter for CFP and a 530-nm longpass filter for YFP
(Chroma). Pinholes were opened to give a depth of focus of 2 lm
for each channel. Scanning was performed on a sequential line-by-
line basis for each channel. The gain for each channel was set to
approximately 75% of dynamic range (12-bit, 4,096 grey levels),
and offsets were set such that backgrounds were zero. Time-lapse
mode was used to collect one pre-bleach image for each channel
followed by bleaching with a minimum of 20 iterations of the 514-
nm argon laser line at maximum power (to bleach YFP). A second
post-bleach image was then collected for each channel. Control non-
bleached areas were acquired for all samples in the same field of
view as bleached cells to confirm specificity of FRET detection. Pre-
and post-bleach TFP and Venus images were then imported into
ImageJ for processing. Briefly, images were smoothed using a 3 9 3
box mean filter, background subtracted and post-bleach images
fade-compensated. A FRET efficiency ratio map over the whole cell
was calculated using the following formula: (TFPpost-bleach  TFPpre-
bleach)/TFPpost-bleach. Ratio values were then extracted from pixels
falling inside the bleach region as well as an equally sized region
outside of the bleach region, and the mean ratio was determined for
each region and is plotted on a histogram. The non-bleach ratio was
then subtracted from the bleach region ratio to give a final value for
the FRET efficiency ratio. Data from images were used only if YFP
bleaching efficiency was > 70%.
Statistical analyses
All statistical tests were performed using GraphPad PrismTM Soft-
ware. Significant differences between means were evaluated by
unpaired two-tailed Student’s t-test. P < 0.05 was considered statis-
tically significant. Exact P-values are shown in figures, except where
P < 0.0001; ns = P > 0.05.
Data availability
The mass spectrometry proteomics data have been deposited to the
ProteomeXchange Consortium via the PRIDE [49] partner repository
with the dataset identifier PXD008591. All additional data can be
accessed by contacting the corresponding author.
Expanded View for this article is available online.
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